Related Experiment Videos
Preventing systemic embolism in patients with abnormal ventricular function
1University of Oklahoma Health Sciences Center, Oklahoma City.
Insights
Aggressive anticoagulant therapy is recommended for acute myocardial infarction patients at high risk of systemic embolism. Antithrombotic treatment may be prudent for other high-risk cardiac conditions due to severe consequences and improved safety.
Area of Science:
- Cardiology
- Thrombosis
- Clinical Trials
Background:
- Systemic embolism poses severe risks, particularly in acute myocardial infarction (AMI) patients.
- High-risk groups include those with anterior transmural infarction, left ventricular aneurysm, dilated cardiomyopathy, and cardiac tumors.
- Lack of definitive trials complicates antithrombotic therapy recommendations for some patient groups.
Purpose of the Study:
- To evaluate the efficacy of anticoagulant therapy in preventing systemic embolism in high-risk AMI patients.
- To discuss the potential benefits of antithrombotic therapy in other patient populations at risk for systemic embolism.
Main Methods:
- Review of clinical trial results supporting anticoagulant use in high-risk AMI.
- Discussion of evidence and rationale for antithrombotic therapy in other cardiac conditions.
Main Results:
- Clinical trials support aggressive anticoagulant therapy for preventing systemic embolism in high-risk AMI patients.
- Antithrombotic therapy effectiveness is documented in other high-risk patient cohorts.
- Recent advancements have improved the safety of long-term anticoagulant treatment.
Conclusions:
- Aggressive anticoagulant therapy is supported for high-risk AMI patients to prevent systemic embolism.
- Antithrombotic treatment may be considered for patients with chronic left ventricular aneurysm, dilated cardiomyopathy, and cardiac tumors, despite incomplete trial data.
- The potential benefits of antithrombotic therapy warrant its use unless contraindicated, given the severe consequences of embolism.
Abstract:
Clinical trial results support the aggressive use of anticoagulant therapy to prevent systemic embolism in patients with acute myocardial infarction who are at high risk for embolism (e.g., anterior transmural infarction). Other patients at risk for systemic embolism include those with chronic left ventricular aneurysm, chronic dilated cardiomyopathy, and cardiac tumors. The role of antithrombotic therapy in these latter groups is incompletely resolved because of a lack of clinical trials. However, in view of the devastating consequences of systemic embolism, the documented effectiveness of antithrombotic therapy in other high-risk patients and the improved safety of long-term anticoagulant treatment in recent years, it may be prudent to use antithrombotic treatment unless contraindicated.